Abbott earnings beat estimates—but it was all downhill from there

Abbott Laboratories continues to grapple with falling sales in its nutrition segment.
Medical Device and Diagnostic Industry (MD+DI)

Abbott’s Mixed Q1: Strong Revenue Growth Tempered by Lowered Guidance

Abbott beats Q1 earnings but trims guidance after $21B Exact Sciences acquisition. Medical devices grow 8.5% while nutrition ...
Fierce Biotech

Abbott lowers EPS guidance on Exact Sciences buy as shares slide

Abbott is dealing with integrating a big new buyout into its business alongside a weaker-than-expected respiratory disease ...

What Abbott Laboratories (ABT)'s First Illinois NEC Verdict Means For Shareholders

Earlier in April 2026, a Chicago jury ordered Abbott Laboratories to pay US$70 million in compensatory and punitive damages ...
The Hill

Warren accuses Abbott Nutrition of years-long cover-up campaign on infant formula risks

Sen. Elizabeth Warren (D-Mass.) sent a letter Wednesday to Abbott Nutrition accusing the company of employing “abusive legal tactics” to cover up health risks with its powdered infant formula product ...

Abbott trims 2026 profit forecast on Exact deal hit, shares fall

By Siddhi Mahatole and Puyaan Singh April 16 (Reuters) - Abbott cut its annual profit forecast on Thursday due to an impact ...